Prostate International Urology

Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →